Logo image of NH

NANTHEALTH INC (NH) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NH - US6301043054 - Common Stock

1.35 USD
-1.18 (-46.64%)
Last: 5/23/2023, 8:00:01 PM
1.3 USD
-0.05 (-3.7%)
After Hours: 5/23/2023, 8:00:01 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to NH. NH was compared to 35 industry peers in the Health Care Technology industry. Both the profitability and financial health of NH have multiple concerns. NH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

NH had negative earnings in the past year.
NH had a negative operating cash flow in the past year.
NH Yearly Net Income VS EBIT VS OCF VS FCFNH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

NH has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NH Yearly ROA, ROE, ROICNH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K

1.3 Margins

Looking at the Gross Margin, with a value of 58.50%, NH is in line with its industry, outperforming 56.82% of the companies in the same industry.
In the last couple of years the Gross Margin of NH has grown nicely.
The Profit Margin and Operating Margin are not available for NH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.62%
GM growth 5Y1.8%
NH Yearly Profit, Operating, Gross MarginsNH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100 -150 -200

0

2. Health

2.1 Basic Checks

NH does not have a ROIC to compare to the WACC, probably because it is not profitable.
NH has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, NH has a worse debt to assets ratio.
NH Yearly Shares OutstandingNH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
NH Yearly Total Debt VS Total AssetsNH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

NH has an Altman-Z score of -10.03. This is a bad value and indicates that NH is not financially healthy and even has some risk of bankruptcy.
NH has a worse Altman-Z score (-10.03) than 79.55% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.03
ROIC/WACCN/A
WACC2.11%
NH Yearly LT Debt VS Equity VS FCFNH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M 400M

2.3 Liquidity

NH has a Current Ratio of 0.64. This is a bad value and indicates that NH is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of NH (0.64) is worse than 81.82% of its industry peers.
A Quick Ratio of 0.64 indicates that NH may have some problems paying its short term obligations.
The Quick ratio of NH (0.64) is worse than 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.64
Quick Ratio 0.64
NH Yearly Current Assets VS Current LiabilitesNH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

0

3. Growth

3.1 Past

NH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -240.38%.
The Revenue has been growing slightly by 7.68% in the past year.
The Revenue has been decreasing by -5.02% on average over the past years.
EPS 1Y (TTM)-240.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.27%
Revenue 1Y (TTM)7.68%
Revenue growth 3Y-4.71%
Revenue growth 5Y-5.02%
Sales Q2Q%4.13%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NH Yearly Revenue VS EstimatesNH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
NH Yearly EPS VS EstimatesNH Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 -2 -4 -6 -8 -10

0

4. Valuation

4.1 Price/Earnings Ratio

NH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NH Price Earnings VS Forward Price EarningsNH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NH Per share dataNH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

NH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NANTHEALTH INC

NASDAQ:NH (5/23/2023, 8:00:01 PM)

After market: 1.3 -0.05 (-3.7%)

1.35

-1.18 (-46.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-10 2023-05-10
Earnings (Next)08-02 2023-08-02
Inst Owners0%
Inst Owner Change0%
Ins Owners206.62%
Ins Owner Change0%
Market Cap10.40M
Revenue(TTM)67.68M
Net Income(TTM)-64.07M
Analysts84.44
Price Target61.2 (4433.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.32
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.45
FCFYN/A
OCF(TTM)-3.61
OCFYN/A
SpS8.79
BVpS-30.72
TBVpS-47.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.5%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.62%
GM growth 5Y1.8%
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.64
Quick Ratio 0.64
Altman-Z -10.03
F-Score3
WACC2.11%
ROIC/WACCN/A
Cap/Depr(3y)35.53%
Cap/Depr(5y)34.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-240.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.27%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.68%
Revenue growth 3Y-4.71%
Revenue growth 5Y-5.02%
Sales Q2Q%4.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.75%
OCF growth 3YN/A
OCF growth 5YN/A

NANTHEALTH INC / NH FAQ

What is the ChartMill fundamental rating of NANTHEALTH INC (NH) stock?

ChartMill assigns a fundamental rating of 1 / 10 to NH.


What is the valuation status of NANTHEALTH INC (NH) stock?

ChartMill assigns a valuation rating of 0 / 10 to NANTHEALTH INC (NH). This can be considered as Overvalued.


Can you provide the profitability details for NANTHEALTH INC?

NANTHEALTH INC (NH) has a profitability rating of 1 / 10.


How financially healthy is NANTHEALTH INC?

The financial health rating of NANTHEALTH INC (NH) is 0 / 10.